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Neurotropic viruses and cerebral palsy: population based
case-control study
Catherine S Gibson, Alastair H Maclennan, Paul N Goldwater, Eric A Haan, Kevin Priest, Gustaaf A Dekker, for the
South Australian Cerebral Palsy Research Group
Abstract
Objective To investigate the association between cerebral palsy
and direct evidence for perinatal exposure to neurotropic
viruses.
Design Population based case-control study.
Setting Adelaide Women’s and Children’s Hospital Research
Laboratory.
Participants and main outcome measures Newborn screening
cards of 443 white case patients with cerebral palsy and 883
white controls were tested for viral nucleic acids from
enteroviruses and herpes viruses by using polymerase chain
reaction. Herpes group A viruses included herpes simplex
viruses 1 and 2 (HSV-1 and HSV-2), Epstein-Barr virus (EBV),
cytomegalovirus (CMV), and human herpes virus 8 (HHV-8),
and herpes group B viruses included varicella zoster virus
(VZV) and human herpes viruses 6 and 7 (HHV-6 and HHV-7).
Results The prevalence of viral nucleic acids in the control
population was high: 39.8% of controls tested positive, and the
prevalence was highest in preterm babies. The detection of
herpes group B viral nucleic acids increased the risk of
developing cerebral palsy (odds ratio 1.68, 95% confidence
interval 1.09 to 2.59).
Conclusions Perinatal exposure to neurotropic viruses is
associated with preterm delivery and cerebral palsy.
Introduction
Intrauterine infection is postulated to be an important contribu-
tor to the development of cerebral palsy.1–3 Previous studies have
investigated surrogate markers of infection, such as chorioam-
nionitis, funisitis, maternal pyrexia, raised values of C reactive
protein, and raised interleukin-6 concentrations.4 This research
used molecular techniques to show the presence of viral nucleic
acids in the blood of newborn babies.
The herpes viruses (including cytomegalovirus (CMV),
herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella
zoster virus (VZV), Epstein-Barr virus (EBV), and human herpes
viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8), and
enteroviruses can all cross the placenta and infect the fetus.5–10
These viruses are potentially neurotropic and could contribute
directly or indirectly to the causation of cerebral palsy. The likeli-
hood of maternal infection resulting in infection of the fetus var-
ies according to the specific virus, whether the infection is
primary or recurrent, and the gestational age of the fetus at the
time of infection. For cytomegalovirus, the risk of transmission to
the fetus for mothers with primary infection is 50%, but only a
minority ( < 1%) of mothers with reactivation (or reinfection)
transmit the virus in utero.11 Once the infection has crossed the
placenta into the fetal circulation, the potential for neuronal
damage is there, directly and also by the fetal inflammatory
response in which pro-inflammatory cytokines may affect the
developing brain adversely. This combination of factors may
determine who develops cerebral palsy.
Some viruses can persist for months or years after the initial
infection.12–15 These viruses may have effects as long as 30 years
after the original infection.16
We investigated associations between potentially neurotropic
viruses and cerebral palsy in a white Australian population. Our
hypothesis was that evidence of perinatal viral infection may be
associated with the development of cerebral palsy.
Methods
Selection of patients and controls
The study population comprised all children with cerebral palsy
born in 1986-99 in South Australia to white mothers (n = 443),
ascertained by South Australia’s cerebral palsy register. The con-
trols were 883 babies born to white mothers from 1986 to
1999.17 We identified newborn screening cards from South Aus-
tralia’s newborn screening programme for each case and
control. We selected four potential controls from screening cards
filed (by date of receipt) before (n = 2) and after (n = 2) the cards
of cases. The date of birth of each control baby was within a few
days of the case baby, the hospital from which we took the
screening cards was of the same category (metropolitan
teaching, metropolitan private, or country), and we took samples
on roughly the same day of life as for the cases. The control
population included a higher proportion of preterm infants
than the general population, as many of the cases of cerebral
palsy were born preterm and had been referred to metropolitan
teaching hospitals. Linkage (with Automatch, version 4.3,
Kennebunk, USA, 1998), using South Australia’s perinatal data-
base, was successful for all cases and 1691 controls. To ensure
that they were not potentially cases of cerebral palsy we excluded
268/1691 (15.8%) controls because they were children of
non-white mothers (n = 102), had a birth defect notified to the
state’s birth defects register (n = 161), or died in the first year of
life (n = 37). We excluded some controls for more than one rea-
son. Random numbers were used to select two controls from the
remaining controls in each group of four, to form the control
population of 886. As three controls had been selected more
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than once, the final number of controls was 883. These samples
were not randomly selected from the entire newborn
population; they were therefore representative of a white popu-
lation without cerebral palsy, infant death, or notifiable birth
defects. The data from all cases and controls were required to be
de-identified before testing for polymorphisms and viral nucleic
acids and statistical analysis. We undertook all testing with blind-
ing to case or control status.
Virus detection
The viruses of interest were categorised into DNA and RNA
viruses. The DNA viruses included HSV-1, HSV-2, VZV, EBV,
CMV, HHV-6, HHV-7, and HHV-8. The RNA viruses included
members of the Enterovirus family. We used two polymerase
chain reactions to detect DNA viruses, using previously
published primers.18 We assigned results to the respective test
groups: the first detected nucleic acids of HSV-1, HSV-2, EBV,
CMV, and HHV-8, hereafter designated herpes group A, and the
second detected nucleic acids of VZV, HHV-6, and HHV-7, here-
after designated herpes group B. Within group A, differentiation
between CMV and the remaining viruses (HSV-1, HSV-2, EBV,
and HHV-8) was possible because of differences in band sizes of
products from the polymerase chain reaction, which were
visually determined by agarose gel electrophoresis.
We used NucleoSpin Tissue Extraction Kit (Macherey-Nagel,
Germany) to extract punches of dried blood (1.2 mm) on
newborn screening cards (collected by heel prick at 3-5 days of
life) for DNA viruses. We chose a phenolic wash method to
extract the newborn screening cards for RNA.19
We used reference RNA and DNA samples extracted from
viral stocks to optimise all conditions for amplification. We
included these reference samples as positive controls for all sub-
sequent amplifications, using dried blood spots in addition to
negative (no template) controls.
Sensitivity of virus detection
We determined the minimum number of detectable viral nucleic
acid copies for each polymerase chain reaction and extrapolated
back to a minimum number of detectable viral nucleic acid cop-
ies per millilitre of blood. The minimum number of detectable
viral nucleic acid copies was 2.8/bloodspot (5.6×103/ml blood)
for enterovirus, 1.6/bloodspot (3.2×103/ml blood) for herpes
group A viruses, and 15/microlitre (3.2×103/ml blood) for
herpes group B viruses.
Statistical analysis
We detected these viral nucleic acids by using newborn screening
samples that had been stored for up to 18 years. We used PEPI,
version 4.0 (Sagebrush Press, Salt Lake City, USA, 2001) to
calculate prevalence proportions and exact 95% confidence
intervals of the viruses in the newborn screening cards tested.
As cases and controls had not been matched for covariates
such as gestational age, we used all controls in our analysis. Data
analysis (GraphPad Instat, version 3.06, San Diego, USA) then
considered cerebral palsy cases and controls by gestational age
range ( < 37 weeks, ≥ 37 weeks, and all gestational ages), type of
cerebral palsy (diplegia, hemiplegia, quadriplegia, and all types)
and virus. Results are expressed as odds ratios with 95%
confidence intervals, comparing positive with negative virus
detection. P values below 0.05 are marked in the tables.
Results
Results were obtained from a total of 414/443 cerebral palsy
samples (93.5%) and 856/883 control samples (96.9%), a differ-
ence that may cause an underestimation of the prevalence of
viral exposure in the cerebral palsy cases (odds ratio 2.22, 95%
confidence interval 1.26 to 3.93). Not all viruses gave a clear
result for each card; the total number of results for each virus was
therefore less than the maximum totals of 414 for cases or 856
for controls. The results are expressed as total readable results.
Prevalence of viruses in control population
We determined the prevalence of viral nucleic acids in the new-
born white population of South Australia without cerebral palsy
(table 1). CMV was the most prevalent virus, with 228 babies
(26.7%) testing positive. In addition, 42 babies (4.9%) were posi-
tive for more than one virus. Of the babies positive for multiple
viruses, the most common combination observed was herpes
group B and CMV, with a prevalence of 3.1% (1.9 to 4.6),
followed by CMV and herpes group A, with a prevalence of 1.1%
(0.5 to 2.1). The remainder of the virus combinations contributed
very small numbers, with prevalences of less than 1%.
We investigated the effect of gestational age on the
prevalence of these viruses because of the high rate of prematu-
rity in the control population. CMV was significantly (P < 0.01)
more prevalent in preterm (82/247) than term (146/608) babies
(33.2% and 24.0%, respectively; odds ratio 1.57, 95% confidence
interval 1.14 to 2.17; table 2). Herpes group A viruses were also
significantly (P < 0.05) more prevalent in preterm (89/247) than
term (167/608) babies (36.0% and 27.5%, respectively; 1.49, 1.09
to 2.04). The same trend was observed for the presence of any
herpes virus, with 44.3% (98/221) of preterm babies testing
positive for any herpes virus, compared with 35.7% (188/526) of
term babies (1.43, 1.04 to 1.97; table 2). No other virus was
significantly different in relation to gestational age. The
difference in the prevalences of any of the viruses between very
preterm babies of less than 32 weeks’ gestation and preterm
babies of 32-36 weeks’ gestation did not reach significance.
Viruses and cerebral palsy
We investigated associations between neurotropic viruses and
cerebral palsy, taking into consideration gestational age and sub-
types of cerebral palsy. Of the 414 cases of cerebral palsy, 131
were diagnosed with diplegia, 119 with hemiplegia, 112 with
quadriplegia, and 52 with other or unspecified subtypes.
All gestational ages
The primary analyses showed a significant association between
any viral exposure and cerebral palsy at all gestational ages (1.30,
Table 1 Prevalence of neurotropic viral nucleic acids, from
individual viruses or groups of viruses, in stored neonatal blood
spots from a control population of South Australian newborns
without cerebral palsy, expressed as percentage positive of the
total tested
Virus Positive Total* Prevalence in % (95% CI)
Enterovirus 22 855 2.6 (1.6 to 3.9)
Cytomegalovirus 228 855 26.7 (23.7 to 29.8)
HSV† 37 855 4.3 (3.1 to 5.9)
Herpes group A‡ 256 855 29.9 (26.9 to 33.1)
Herpes group B§ 54 715 7.6 (5.7 to 9.7)
Any herpes virus¶ 286 747 38.3 (34.8 to 41.9)
Any virus** 298 749 39.8 (36.3 to 43.4)
Multiple viruses (≥2) 42 856 4.9 (3.6 to 6.6)
*The number of samples with a valid test result varied between the different polymerase chain
reaction tests. This accounts for the slightly different total number of babies tested for each
virus.
†HSV-1, HSV-2, EBV, HHV-8.
‡HSV-1, HSV-2, EBV, CMV, HHV-8.
§VZV, HHV-6, HHV-7.
¶HSV-1, HSV-2, EBV, CMV, HHV-8, VZV, HHV-6, HHV-7.
**All herpes viruses or enterovirus.
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1.00 to 1.67). The detection of herpes group B viral nucleic acids
increased the risk of developing all types of cerebral palsy, with
an odds ratio of 1.68 (1.09 to 2.59). This increased risk was also
observed for the diplegic (1.93, 1.03 to 3.61) and hemiplegic
(2.07, 1.10 to 3.88) subtypes of cerebral palsy and herpes group
B viruses. Associations did not reach significance for any of the
other viruses.
Gestational age ≥37 weeks
The risk of developing cerebral palsy for a gestational age of 37
weeks or more increased with the detection of any herpes virus,
with an odds ratio of 1.52 (1.09 to 2.13), and also with the detec-
tion of any virus (1.64, 1.17 to 2.28). Herpes group B viruses were
associated with the development of diplegia (2.45, 1.02 to 5.89)
and hemiplegia (2.38, 1.15 to 4.92). The risk of developing
cerebral palsy for gestational age of 37 weeks or more increased
with the detection of any herpes virus (1.52, 1.09 to 2.13) and
also with the detection of any virus (1.64, 1.17 to 2.28). Associa-
tions did not reach significance for any of the other viruses (table
3).
Gestational age <37 weeks
The detection of herpes group A viral nucleic acids decreased
the risk of developing all types of cerebral palsy for gestational
age < 37 weeks (0.65, 0.43 to 0.99; table 4). Detection of herpes
group B increased the risk for quadriplegia for gestational age
< 37 weeks (2.87, 1.09 to 7.59). We found no other significant
associations for any of the other viruses (table 4).
Combination viruses at any gestational age
The presence of more than one virus was not associated with the
risk of developing cerebral palsy at any gestational age (1.13, 0.65
to 1.98). Comparing term born babies with cerebral palsy with
term born controls (1.29, 0.64 to 2.61), or preterm babies with
cerebral palsy with preterm controls (0.98, 0.38 to 2.53), did not
show any associations either.
Discussion
Perinatal exposure to and infection with viruses are associated
with cerebral palsy in the newborn. Our findings reinforce the
possibility of a complex and heterogeneous relation between
exposure to viral infections and subtypes of cerebral palsy at dif-
Table 2 Prevalence of neurotropic viral nucleic acids, from individual
viruses or groups of viruses, in stored neonatal blood spots from a control
population of term and preterm South Australian newborns without cerebral
palsy, expressed as percentage positive of the total tested
Virus and gestation in
weeks Positive Total†
Prevalence in %
(95% CI) Odds ratio (95% CI)
Enterovirus
≥37 17 608 2.8 (1.6 to 4.4) Reference
<37 5 247 2.0 (0.7 to 4.7) 0.72 (0.26 to 1.97)
Cytomegalovirus
≥37 146 608 24.0 (20.7 to 27.6) Reference
<37 82 247 33.2 (27.4 to 39.4) 1.57 (1.14 to 2.17)*
HSV‡
≥37 29 608 4.8 (3.2 to 6.8) Reference
<37 8 247 3.2 (1.4 to 6.3) 0.67 (0.30 to 1.48)
Herpes group A§
≥37 167 608 27.5 (24.0 to 31.2) Reference
<37 89 247 36.0 (30.0 to 42.4) 1.49 (1.09 to 2.04)**
Herpes group B¶
≥37 39 503 7.8 (5.6 to 10.4) Reference
<37 15 212 7.1 (4.0 to 11.4) 0.91 (0.49 to 1.68)
Any herpes virus††
≥37 188 526 35.7 (31.6 to 40.0) Reference
<37 98 221 44.3 (37.7 to 51.2) 1.43 (1.04 to 1.97)**
Any virus‡‡
≥37 199 528 37.7 (33.5 to 42.0) Reference
<37 99 221 44.8 (38.1 to 51.6) 1.34 (0.98 to 1.84)
Odds ratios (95% confidence intervals) for <37 weeks’ gestation compared with ≥37 weeks’
gestation.
*P<0.01 compared with prevalence in babies born at term. **P<0.05 compared with
prevalence in babies born at term.
†The number of samples with a valid test result varied between the different polymerase chain
reaction tests. This accounts for the slightly different total number of babies tested for each
virus.
‡HSV-1, HSV-2, EBV, HHV-8.
§HSV-1, HSV-2, EBV, CMV, HHV-8.
¶VZV, HHV-6, HHV-7.
†† HSV-1, HSV-2, EBV, CMV, HHV-8, VZV, HHV-6, HHV-7.
‡‡All herpes viruses or enterovirus.
Table 3 Odds ratios (with 95% confidence intervals) for specified viruses in
babies with cerebral palsy at ≥37 weeks’ gestation compared with controls


























































1.12 (0.25 to 4.97)






1.29 (0.74 to 2.24)
Numbers of positive test results for each virus for cases of cerebral palsy are listed in
parentheses in the first column.
*HSV-1, HSV-2, EBV, HHV-8.
†VZV, HHV-6, HHV-7.
‡Significant at the 0.05 level.
§HSV-1, HSV-2, EBV, CMV, HHV-8.
¶HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7, HHV-8.
**All herpes viruses or enterovirus.
Table 4 Odds ratios (with 95% confidence intervals) for specified viruses in
babies with cerebral palsy at <37 weeks’ gestation compared with controls








































































Numbers of positive test results for each virus for CP cases are listed in parentheses in the
first column.
*HSV-1, HSV-2, EBV, HHV-8.
†VZV, HHV-6, HHV-7.
‡Significant at the 0.05 level.
§HSV-1, HSV-2, EBV, CMV, HHV-8.
¶HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7, HHV-8.
**All herpes viruses or enterovirus.
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ferent gestational ages. Other cofactors may trigger neurotropic
damage. We examined the association between cerebral palsy
and perinatal exposure to neurotropic viruses. The findings were
based on the detection of viral nucleic acids from newborn
screening card blood spots collected within a few days of birth,
and where detected, the findings indicate intrauterine or early
neonatal viral exposure or infection.
Caveats
Post hoc analyses were performed on the individual viruses and
their combinations, increasing the likelihood of identifying
chance statistical associations. Because of the small numbers in
some of the subanalyses, other associations cannot be excluded
with confidence. Where associations are seen in one gestational
age range, similar trends are seen in the same subgroup of
cerebral palsy with the same virus in other gestational age
ranges. This implies that these may indicate true causal relations
and may not be attributed to chance. These associations require
further study.
Viral associations with preterm birth and cerebral palsy
We document the prevalence of certain viral nucleic acids in a
white control population and have shown that stored neonatal
blood spots can be used to investigate associations with cerebral
palsy. Exposure to viral nucleic acids seems very common in our
control population, with a prevalence of 39.8% for any of the
viruses tested, and these were mostly herpes viruses. Nearly 5%
of our control population tested positive for more than one
virus. The prevalence of CMV was significantly higher in those
controls born at less than 37 weeks’ gestation than in controls
born at term (33.2% v 24.0%), implying that the presence of viral
infectious agents in the womb is also associated with subsequent
preterm delivery.20–23
Using this large cohort of cases of cerebral palsy and controls
we identified specific viral DNA and RNA nucleic acid sequences
and showed that exposure to viral nucleic acids (and presumably
infectious virus), in particular herpes group B, is associated with
cerebral palsy. The results show a 1.5-2.5 times increased risk of
developing cerebral palsy after perinatal exposure to herpes
group B viruses. The prevalence of herpes group B viruses was
7.6% for controls and 12.1% for babies with cerebral palsy, giving
a potential attributable risk of 4.5% of all cases of cerebral palsy
if a causal relation exists. These results also show an increased
risk of developing cerebral palsy in term babies after perinatal
exposure to any virus. In contrast, the results from table 4 imply
negative associations between perinatal exposure to viral nucleic
acids and subsequent cerebral palsy for babies born before term.
These conflicting results may be due to the higher prevalence of
viral infection in control babies born before term, thus diluting
any positive association between viral infection and cerebral
palsy for preterm babies. Exposure late in gestation may not
result in preterm birth, instead having direct effects on the brain,
whereas exposure early in gestation may result in preterm birth
but increase the risk of neuropathology associated with
prematurity. In this manner, exposure to perinatal viral infection
may be indirectly associated with cerebral palsy.
Viral loads
Although our study used non-quantitative methods of and well
documented primers for polymerase chain reaction, viral loads
may vary over a wide range. Low viral loads may not be sufficient
to precipitate preterm birth, but continuing intrauterine
development in the presence of infection may allow the infection
to contribute to permanent neuropathology. On the other hand,
high viral loads may initiate or result in preterm birth and
increase the risk of neurological damage associated with prema-
turity or infection, or both. We plan prospective studies quantify-
ing viral loads to test this theory. Prospective studies will allow
access to a wider range of clinical data and correlation with clini-
cal evidence of infection.
Future directions
Our results do not necessarily indicate active congenital or neo-
natal infection. Detection of viral nucleic acids in the blood of
neonates indicates only exposure to the respective virus or
viruses, and not an inflammatory response. Given the small sam-
ple volume and the limit of detection of one to 10 viral nucleic
acid copies, it could be inferred that true viraemic infection was
occurring. It therefore also seems unlikely that presence of viral
nucleic acid merely reflected transfer of maternal cells to the fetal
circulation via the placenta. Prospective investigations are
required to follow women through pregnancy, testing antenatal
maternal blood samples for viral nucleic acids, and umbilical
cord blood to determine if there is active infection in the fetus or
neonate by examining leukocytes for the presence of viral
antigens associated with active viral replication and the presence
and severity of the inflammatory response of the fetus. The
advent of widespread childhood vaccination against VZV, which
has been available in South Australia for 10 years, will provide an
opportunity to investigate the impact of maternal VZV infection
and reactivation on the development of cerebral palsy. It will be
interesting to observe if a decline occurs in the rates of cerebral
palsy in the next generation, after the vaccination of their moth-
ers, in a way similar to that of the rubellavirus vaccine in reduc-
ing the teratogenic effects of rubella during pregnancy.
Pathogenesis
It is unclear how perinatal exposure to viral infection causes sub-
sequent brain damage and cerebral palsy. If the virus is able to
cross the blood-brain barrier, it is capable of setting up infection
in the brain and directly damaging vulnerable neuronal tissue.
Herpesviruses are capable of establishing themselves within the
brain, where they can remain latent indefinitely or reactivate and
cause damage. Alternatively, products of infection can be
released locally and into the circulation. These products can
cross the blood-brain-barrier, as a result of either the barrier’s
immaturity24 or the release of pro-inflammatory cytokines that
impair its integrity.25 26 Having penetrated the blood-brain-
barrier, these pro-inflammatory cytokines—such as tumour
necrosis factor —can cause direct damage to developing white
matter, resulting in periventricular leukomalacia, with possible
stimulation of fetal microglia to produce more TNF-27 and dis-
ruption of the endothelium and ependyma.26
The high prevalence of exposure to viral infection in our
control population indicates that “triggers” or cofactors are
needed before brain damage can occur. Such triggers may
include genetic susceptibility to infections—for example,
cytokine polymorphisms that increase or decrease the host
immune response to the infection. Disruption of barriers such as
the placenta and blood-brain barrier as a result of fetal
infarctions secondary to inherited thrombophilia may also have
a role in the transmission and establishment of infections. Infec-
tion triggering thrombosis in the fetus with thrombophilia could
also be postulated. An association between fetal thrombophilia
and cerebral palsy has also been found in our cohort.28
Conclusions
Our study has shown that exposure to viral infection is common
in newborn babies in South Australia, especially in preterm
babies. The risk of cerebral palsy is nearly doubled with exposure
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to herpes group B viruses but may require other factors, such as
genetic susceptibility to infection and inherited thrombophilia or
involvement of other clinical events—for example, growth
restriction or prematurity—for brain damage and subsequent
cerebral palsy to occur. Future studies are planned to investigate
these factors.
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What is already known on this topic
Preterm birth and choriamnionitis are associated with
cerebral palsy and infection with neurotropic viruses in
neonates and infants can lead to neurological disability,
including cerebral palsy
What this study adds
Stored dried neonatal blood spots, from babies who were
diagnosed subsequently to have cerebral palsy, and from
control babies, often contain nucleic acids from neurotropic
viruses
Herpes group A (including cytomegalovirus) nucleic acids
were found more often in neonatal blood spots of preterm
control babies than in control babies born at term
Herpes group B nucleic acids were found more often in
neonatal blood spots of babies who were diagnosed
subsequently to have cerebral palsy than in control babies
The presence of neurotropic viral nucleic acids in the blood
of newborns and the subsequent diagnosis of cerebral palsy
are significantly associated
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